| Accelerating genomics-based surveillance for COVID-19 response in Africa SK Tessema, SC Inzaule, A Christoffels, Y Kebede, T de Oliveira, ... The Lancet Microbe 1 (6), e227-e228, 2020 | 35 | 2020 |
| Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa SC Inzaule, P Ondoa, T Peter, PN Mugyenyi, WS Stevens, TFR de Wit, ... The Lancet Infectious Diseases 16 (11), e267-e275, 2016 | 84 | 2016 |
| Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis RS Boerma, KCE Sigaloff, AS Akanmu, S Inzaule, ... Journal of Antimicrobial Chemotherapy 72 (2), 365-371, 2017 | 92 | 2017 |
| Antiretroviral-drug resistant mutations and genetic diversity in HIV-1 infected individuals in Nigeria OR Negedu-Momoh, OS Olonitola, LE Odama, HI Inabo, HA Mbah, ... World Journal of AIDS 2014, 2014 | 9 | 2014 |
| Association between HIV-1 subtype and drug resistance in Nigerian infants B Chaplin, AS Akanmu, SC Inzaule, JO Samuels, P Okonkwo, O Ilesanmi, ... Journal of Antimicrobial Chemotherapy 74 (1), 172-176, 2019 | 6 | 2019 |
| Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings ENJ Semengue, D Armenia, S Inzaule, MM Santoro, B Dambaya, ... Journal of Antimicrobial Chemotherapy 76 (5), 1277-1285, 2021 | 16 | 2021 |
| Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis AK Ahluwalia, S Inzaule, RC Baggaley, M Vitoria, R Schaefer, ... AIDS 36 (13), 1897-1898, 2022 | 5 | 2022 |
| Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor–containing antiretroviral … S Bertagnolio, L Hermans, MR Jordan, S Avila-Rios, C Iwuji, A Derache, ... The Journal of Infectious Diseases 224 (3), 377-388, 2021 | 47 | 2021 |
| Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study SC Inzaule, RL Hamers, M Noguera-Julian, M Casadellà, M Parera, ... The Lancet HIV 5 (11), e638-e646, 2018 | 70 | 2018 |
| Combined antiretroviral treatment modification among HIV infected patients in New Nyanza Provincial General Hospital, Western Kenya SC Inzaule | | 2012 |
| Correction: long-term antiretroviral treatment adherence in HIV-infected adolescents and adults in Uganda: a qualitative study SC Inzaule, RL Hamers, C Kityo, TF Rinke de Wit, M Roura Plos one 12 (2), e0172077, 2017 | 2 | 2017 |
| COVID-19 and indirect health implications in Africa: Impact, mitigation measures, and lessons learned for improved disease control SC Inzaule, P Ondoa, MM Loembe, YK Tebeje, AEO Ouma, ... PLoS Medicine 18 (6), e1003666, 2021 | 63 | 2021 |
| Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens SC Inzaule, RL Hamers, M Doherty, RW Shafer, S Bertagnolio, ... The Lancet Infectious diseases 19 (7), e246-e252, 2019 | 55 | 2019 |
| Does tenofovir-containing first-line antiretroviral therapy mitigate the impact of pretreatment non-nucleoside reverse transcriptase inhibitor drug resistance? SC Inzaule, TF Rinke de Wit, RL Hamers, ... Clinical Infectious Diseases 68 (12), 2158-2160, 2019 | 3 | 2019 |
| Dolutegravir drug-resistance monitoring in Africa V Kouamou, S Inzaule, J Manasa The Lancet HIV 8 (11), e664-e666, 2021 | 9 | 2021 |
| Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya SC Inzaule, RL Hamers, I Mukui, K Were, P Owiti, D Kwaro, TFR de Wit, ... Aids 31 (10), 1495-1498, 2017 | 22 | 2017 |
| Entangled epidemics: tackling vaccine-preventable diseases in the era of frequent epidemics in Africa V Kouamou, S Inzaule The Pan African Medical Journal 46, 2023 | | 2023 |
| Epidemiology of HIV drug resistance in low-and middle-income countries and WHO global strategy to monitor its emergence S Bertagnolio, MR Jordan, A Giron, S Inzaule Current Opinion in HIV and AIDS 17 (4), 229-239, 2022 | 13 | 2022 |
| Evaluation of Pima CD4+ point-of-care device in western Kenya for potential use in field settings [Abstract 624] C Zeh, SC Inzaule, F Otieno, B Oyaro, R Ndivo, CE Rose Proceedings of the 21st Conference on Retroviruses and Opportunistic …, 2014 | 4 | 2014 |
| Evaluation of the performance of Abbott m2000 and Roche COBAS Ampliprep/COBAS Taqman assays for HIV-1 viral load determination using dried blood spots and dried plasma spots in … C Zeh, K Ndiege, S Inzaule, R Achieng, J Williamson, J Chih-Wei Chang, ... PloS one 12 (6), e0179316, 2017 | 41 | 2017 |
